Advertisement

Topics

Companies Related to "Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma" [Most Relevant Company Matches] RSS

19:33 EST 16th February 2019 | BioPortfolio

Here are the most relevant search results for "Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma" found in our extensive corporate database of over 50,000 company records.

Showing "Lenalidomide Rituximab Maintenance Therapy Treating Patients With Cell" Companies 1–25 of 6,100+

Relevant

Biogen Idec

Scientific excellence that achieves new standards of care drives the company's work. 17 products are currently in clinical development addressing a variety of key medical needs.With patients in more than 90 countries, two blockbuster drugs lead Biogen Idec's product lineup:RITUXAN® (rituximab) was discovered by Biogen Idec for the treatment of certain B-cell non-Hodgkin's lymphomas (NHL). The com...


Allogene Therapeutics, Inc.

Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Founded and led by former Kite Pharma executives who bring unrivaled clinical development acumen in cell therap...

MEDINET Co., Ltd. and MaxCyte, Inc.

MEDINET is a world leading company in cell therapy, supporting medical service providers in Japan. Through its service, MEDINET provides medical institutions with advanced technologies and knowhow in: cell processing and culturing, quality control, and facility management with respect to the immuno-cell therapy. MEDINET has extensive experience in autologo...


ViroLogic

ViroLogic, a privately held South San Francisco-based biotechnology company, is a leader in the development of novel therapy guidance tools to enable patients, physicians, and medical reimbursers to make rational treatment decisions in the management of viral diseases. The company's proprietary technology is also being used in the fields of viral pharmacogenomics to identify, analyze, and select n...

Arbios Systems, Inc.

Arbios Systems, Inc. is developing proprietary medical devices and cell-based therapies to enhance the survival of millions of patients each year who experience, or are at risk for, life-threatening episodes of liver failure. The Arbios product candidate portfolio includes the SEPET™ Liver Assist Device, a novel blood purification therapy that provides enhanced “liver dialysis,” and the H...

Cell Therapy Foundation

The Cell Therapy Foundation is a not-for-profit organization committed to advancing the treatment of disease using adult stem cells. Emerging as a leader in raising funds for adult stem cell research, Cell Therapy Foundation strives to increase awareness about adult stem cells, to fund adult stem cell research addressing several specific diseases, and to accelerate the rate of research and clini...

Cell Medica Limited

Cell Medica is a cellular therapeutics company engaged in the development, manufacturing and marketing of T cell immunotherapy approaches for the treatment of infections and cancers related to oncogenic viruses. The Company’s lead cell product, CytovirTM CMV, for the treatment and prevention of cytomegalovirus (CMV) infections in patients following al...

Aastrom Biosciences Incorporated

Aastrom Biosciences, Inc. (Nasdaq: ASTM) is developing automated cell therapy systems designed to enable on-site cell production for therapeutic procedures using living cells in patients treated for cancer and other diseases and cells used in the restoration of normal tissues. The Company has received approval to affix the CE Mark to the various components of the AastromReplicell™ System, the SC...

Genetronics Biomedical

Genetronics' most advanced effort involves treating those with head and neck cancer, a particularly devastating cancer that can severely limit the ability of these patients to see, taste, hear, talk, breathe, or swallow. Genetronics received approval from the U.S. Food and Drug Administration and initiated Phase II multi-center clinical trials at nine sites in the U.S. The trials test the effectiv...

Cell Therapy Catapult

The Cell Therapy Catapult is a centre of translational excellence for cell therapy and regenerative medicine. Its vision is for the UK to be a global leader in the development, delivery and commercialisation of cell therapy, making it a location for business start-up and growth. Based in London at Guy's Hospital, the centre takes products into early clinical ...

Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes ...

Physical Therapy Pal

Physical Therapy Pal (PT PAL) is the first clinical HIPAA-compliant mobile application used between physical therapists and patients. PT PAL helps improve outcomes by engaging patients in their therapy. PT PAL gives visibility into patient regimen adherence and the ability to monitor and modify therapy prescriptions remotely. PT PAL is an aid ...

ADVANCED CELL & GENE THERAPY, LLC

ADVANCED CELL & GENE THERAPY, LLC, is a consulting firm serving biotechnology companies, clinical laboratories, and biotechnology investors. We provide practical, experienced guidance in development, GMP/GTP manufacturing, and regulatory compliance, as well as comprehensive scientific and technical strategic analysis of business opportunities in cell, gene and tissue therapies.

Cancer Therapeutics, Inc.TM

Founded in 1991, Cancer Therapeutics, Inc.TM (CTI) is a biotherapy company that is a leader in activated cell technology for cancer therapy. CTI's laboratory offers access to technologies grouped under the modality of Biotherapy. Biotherapy is based on treatments that enhance the patient's own immune system to attack the invading cancer. Research has shown cancer to be a highly individualized dise...

TrakCel

TrakCel's cell therapy process management solution improves clinical study efficacy and accelerates product scale-up/scale-out by implementing communications technology to integrate the supply chain from end-to-end. The technology provides interactive instructions to professionals within the cell therapy supply chain and gives stakeholders on-demand visibi...

cellasys GmbH

"cellasys offers system solutions for online analysis of living cells. These include services as research and development, production and maintenance of cell based assays. Furthermore we are consultant for developent of applications, data analysis and data interpretation. The cell based assays monitor different parameters directly at living cells. These parameters are extracellular acidification (...

Emmerex

Emmerex is an early stage bio-pharmaceutical company. It aims to bring to market an anti-cancer therapy. The Emmerex therapy arose as a result of several years' biological research. It has already been proven to be safe in patients. The Emmerex therapy utilises the patients' own innate ability to fight cancer. It cuts off nutrient source of the cancer and attacks the tumours directly. The Emmerex ...

VisCardia Inc

VisCardia based in Portland, OR is developing a novel implantable device therapy for treating heart failure, a condition that afflicts 10 million patients in the U.S. and Europe. To learn more about VisCardia, visit: http://www.viscardia.com

VisCardia Inc.

VisCardia, based in Portland, OR, is developing a novel implantable device therapy for treating heart failure, a condition that afflicts 10 million patients in the U.S. and Europe. To learn more about VisCardia, visit: http://www.viscardia.com.

Genetix Pharmaceuticals, Inc.

Genetix Pharmaceuticals, Inc. is an emerging leader in treatments for severe genetic disorders based on a breakthrough gene therapy platform that uses a patient’s own genes to treat his/her disorder. Taking stem cells from a patient’s own bone marrow, Genetix uses a proprietary lentiviral technology to modify the genes and deliver corrective stem ...

Asterias Biotherapeutics, Inc.

Asterias Biotherapeutics is a subsidiary of BioTime, Inc., whose mission is to acquire and develop best in class cell therapy product candidates. Our first acquisition was the stem cell assets of Geron Corporation, which was completed on October 1, 2013. That acquisition includes Geron’s entire cell therapy intellectual property portfolio, existing co...

Vasomedical

Vasomedical Inc. provides superior medical products and services that address unmet clinical needs in the management of patients with heart disease. The company’s core technology, EECP® therapy, provides healthcare professionals a non-invasive therapy for patients suffering from cardiovascular diseases. EECP therapy helps patients and their families lead active and productive lives. With ov...

Brooklyn ImmunoTherapeutics LLC

Brooklyn ImmunoTherapeutics (formerly IRX Therapeutics) is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies.

ORFLO Technologies

ORFLO (www.orflo.com) is a life sciences company developing and marketing revolutionary instrumentation protein and cell analysis. At the core of ORFLO’s instrumentation is a patent protected disposable, micro-fluidic, electronic optic flow cell. ORFLO’s instruments provide a powerful unique window to cell analysis by directly measuring fluoresce...

Cell Genesys

Cell Genesys is a leader in the development and commercialization of innovative therapeutic products for cancer based on gene therapy technologies. The company has a broad portfolio of clinical stage product development programs, the largest patent portfolio in the gene therapy field, proprietary gene delivery technologies, and a strong balance sheet, all of which have helped position Cell Genesy...


More From BioPortfolio on "Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks